To include your compound in the COVID-19 Resource Center, submit it here.
TG Therapeutics began the open-label, U.S. Phase IIb UNITY-DLBCL trial to evaluate oral TGR-1202 daily
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury